Fresenius reveals FDA warning letter

March 14, 2013 by Brad Perriello

Dialysis giant Fresenius says an FDA warning letter about a plant in Ogden, Utah, isn't likely to have an effect on its sales and earnings guidance.


Fresenius (NYSE:FMS) said today that an FDA warning letter sent to its North American division isn't likely to have an impact on its sales and earnings guidance for this year.

The German dialysis giant said the U.S. watchdog agency warned it about problems with its design verification and validation procedures at a plant in Ogden, Utah.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.